Physician profile
Kalpana Reddy
NPI 1376647701
$470,123.83
in general payments reported to CMS, 2019-2025
44 companies · $52K in 2025
The $52K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $63K · 2021: $39K · 2022: $101K · 2023: $81K · 2024: $52K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $162K · Food and Beverage: $19K · Travel and Lodging: $4,331 · Consulting Fee: $188 · Education: $65.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $162,105.50 |
| Food and Beverage | $18,595.99 |
| Travel and Lodging | $4,330.88 |
| Consulting Fee | $187.89 |
| Education | $65.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $119,500.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78,211.23 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $69,141.15 | 2019-2024 | Farxiga, Lokelma |
| Mannkind Corporation | $60,298.24 | 2019-2025 | V-Go, Afrezza |
| Sanofi-Aventis U.S. LLC | $47,935.78 | 2019-2025 | |
| Lilly USA, LLC | $25,098.16 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Cequr Corporation | $19,022.16 | 2022-2025 | Cequr Simplicity |
| Intuity Medical INC | $16,833.72 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Janssen Pharmaceuticals, INC | $9,947.22 | 2019-2022 | |
| Valeritas, INC. | $8,101.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,877.25 | 2021-2025 | |
| Beta Bionics, INC. | $1,196.47 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $1,051.35 | 2021-2025 | Unithroid |
| Dexcom, INC. | $811.40 | 2020-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $621.03 | 2019-2023 | Verquvo, Steglatro |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $580.58 | 2020-2025 | Tepezza, Evenity, Prolia |
| Horizon Therapeutics Plc | $579.56 | 2019-2023 | Tepezza |
| Zealand Pharma US, INC. | $538.08 | 2020-2021 | |
| Abbvie INC. | $529.93 | 2019-2025 | |
| Abbott Laboratories | $525.37 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Insulet Corporation | $369.17 | 2019-2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $364.52 | 2020-2023 | Livalo |
| Corcept Therapeutics | $334.23 | 2021-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.47 | 2019-2024 | Cycloset |
| Tandem Diabetes Care, INC. | $298.12 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $294.80 | 2023-2025 | Yorvipath |
| Madrigal Pharmaceuticals | $280.87 | 2025 | Rezdiffra |
| Amphastar Pharmaceuticals, INC. | $237.23 | 2023-2025 | Baqsimi |
| Novartis Pharmaceuticals Corporation | $209.72 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $208.53 | 2020-2022 | |
| Ibsa Pharma INC. | $184.75 | 2019-2024 | Tirosint, Licart, Licart |
| Amarin Pharma, INC. | $154.66 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $125.23 | 2022-2025 | Contrave |
| Becton, Dickinson and Company | $93.66 | 2022 | |
| Avvisto Therapeutics, LLC | $38.87 | 2024 | Cycloset |
| Medtronic Minimed, INC. | $38.07 | 2019-2020 | |
| Vistapharm, INC. | $37.86 | 2021 | |
| Ascensia Diabetes Care US INC. | $33.29 | 2023 | |
| Astellas Pharma US INC | $26.73 | 2025 | Veozah |
| Eisai INC. | $20.31 | 2019 | |
| Esperion Therapeutics, INC. | $17.82 | 2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $16.06 | 2023 | Inpefa |
| Medicure Pharma INC. | $13.67 | 2025 | Zypitamag |
| Medtronic, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalpana Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.